TXG is trading at $33.05 (down 4.5%) in after-hours trading as investors lock in gains following a sharp regular-session rally and an updated analyst outlook.
- Barclays maintained its Overweight rating on 10x Genomics and raised its price target to $40.00, which likely prompted profit-taking after recent price strength.
- The move appears to be stock-specific rather than macro-driven, with traders reacting to the updated valuation and recent volatility amid a mixed broader market.